Vivek Subbiah: KRAS inhibitors are here to stay

Vivek Subbiah shared on X:

“KRAS inhibitors are here ASCO24 & here to stay for all future ASCO, ESMO & all meetings. Some of the KRAS drugs that have entered trials featured in this editorial JCO Oncology Practice. Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer.”

Read further.
Source: Vivek Subbiah/X
 .
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA).

He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world.